Welcome to our dedicated page for Phibro Animal Health news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health stock.
Phibro Animal Health Corporation reports developments in animal health, mineral nutrition and performance products for food-animal markets. The company develops, manufactures and markets antibacterials, anticoccidials, nutritional specialty products, vaccines and mineral nutrition products for poultry, swine, beef and dairy cattle, and aquaculture in the United States and international markets.
Recurring PAHC news includes quarterly results and guidance, cash dividend declarations on Class A and Class B common stock, investor conference participation and regulatory updates affecting antimicrobial products such as virginiamycin and bacitracin. Company updates also address product portfolio activity, acquisition-related effects, input and distribution costs, foreign-currency impacts and tools such as PhibroVet for veterinary prescription management.
Phibro Animal Health Corporation (NASDAQ: PAHC) announced that the FDA will hold a public hearing on March 10, 2022, regarding its product Mecadox® (carbadox). This antibiotic has been used in the U.S. for 50 years to control bacterial diseases in swine. The FDA seeks data on the product's safety, following past concerns about carcinogenic residues. Phibro has been proactively providing research to confirm the product's safety, stating that it will defend its continued market availability. They anticipate the hearing will support the safe use of Mecadox.
Phibro Animal Health Corporation (NASDAQ:PAHC) is set to announce its second quarter financial results on February 9, 2022, after market close. A conference call and webcast will follow on February 10, 2022, at 9:00 AM ET. Interested parties can join via the company's investor relations website or by calling provided numbers. Phibro develops and supplies a range of animal health products, promoting sustainable livestock management and food production. For more details, visit www.pahc.com.
Phibro Animal Health Corporation (NASDAQ:PAHC) announced its participation in the 4th Annual Evercore ISI Virtual Conference on December 1, 2021, at 8:00 AM ET. Chief Financial Officer Damian Finio and Executive Vice President Daniel Bendheim will present to financial analysts and investors. Participants can access the live audio presentation on the Phibro Investor Relations Website, and a replay will be archived for later listening. Phibro is a global developer and supplier of animal health and mineral nutrition products aimed at supporting sustainable food production.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its Q1 financial results for the period ending September 30, 2021. Net sales increased by 10% to $215 million, while net income dropped 47% to $7 million. Diluted EPS fell by 47% to $0.16. The company raised its fiscal year net sales guidance to $860-$890 million, citing strong product demand, especially in nutritional specialties and vaccines, despite challenges from increased costs. Gross profit margins decreased to 30.1%. The outlook includes further price adjustments to offset rising freight costs.
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) has declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend will be payable on December 15, 2021, to stockholders of record as of the close of business on November 24, 2021. Phibro is a global developer and supplier of animal health and mineral nutrition products, aimed at supporting livestock health and sustainability.
Phibro Animal Health Corporation (NASDAQ: PAHC) will release its first quarter financial results on November 2, 2021, after market close. A conference call and webcast are scheduled for November 3, 2021, at 9:00 AM ET. Investors can access the presentation through the company’s investor relations website. This event is expected to provide key insights into the company's financial performance and future guidance, an important aspect for stakeholders.
Phibro Animal Health Corporation (NASDAQ:PAHC) announced its participation in the 30th Annual Credit Suisse Virtual Healthcare Conference on November 9, 2021, at 4:20 PM ET. Key executives, including Chairman Jack Bendheim, CFO Damian Finio, and EVP Daniel Bendheim, will address financial analysts and investors during the event. The live audio presentation will be accessible via the company's Investor Relations Website, with a replay available later.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported strong Q4 and full-year results for fiscal year 2021, with net sales of $220 million in Q4, up 19% year-over-year, and $833 million for the year, an increase of 4%. Net income surged to $17 million in Q4, reflecting a 203% increase, and $54 million for the year, a 62% rise. Diluted EPS also rose to $0.42 for Q4 and $1.34 for the full year. Guidance for FY 2022 projects net sales of $840-$870 million and net income of $45-$47 million.
Phibro Animal Health Corporation (Nasdaq: PAHC) will participate in the Morgan Stanley Virtual Global Healthcare Conference on September 9, 2021, at 9:30 AM ET. Chairman and CEO Jack Bendheim, CFO Damian Finio, and EVP Daniel Bendheim will address analysts and investors during the session. The live audio presentation can be accessed on the company’s Investor Relations website, with a replay also available. Phibro focuses on developing a wide range of animal health and mineral nutrition products for livestock.
Phibro Animal Health Corporation (Nasdaq:PAHC) will participate in the Bank of America Virtual Global Healthcare Conference on September 15, 2021, at 9:10 AM ET. Chief Financial Officer Damian Finio will present to financial analysts and investors, with a live audio available on the company's Investor Relations website. A replay will also be archived for future access. Phibro is a global developer and supplier of animal health and nutrition products, helping produce healthy food sustainably.